Testa vår nya webbplats och uppdaterade nyhetsrum för att ta del av aktuella nyheter, rapporter och mycket mer.

Guard Therapeutics receives patent approval for RMC-035 in China

Guard Therapeutics today announces that the company has received a grant from the Chinese Patent Office (China National Intellectual Property Administration) for its patent application no. 201780018244.4 that protects the company's biological investigational drug RMC-035 as a product.

The approved patent is officially announced as patent no. CN 108779157 B and will be valid until 2037. The approval means that the company's patent portfolio and thus the commercial potential for RMC-035 are further strengthened.
"The positive news from the Chinese Patent Office means that Guard Therapeutics has now received patent protection for RMC-035 in all major pharmaceutical markets around the world, which also include the US, EU and Japan. China is considered to be an important market for acute kidney injuries, and this provides the best possible conditions for a future commercialization of our investigational drug", says Tobias Agervald, CEO of Guard Therapeutics. 

For further information, please contact:

Tobias Agervald, CEO
Telephone: +46 8 670 65 51
E-mail: [email protected]  

About Guard Therapeutics

Guard Therapeutics is a Swedish biotech company that identifies and develops new therapies for diseases with a great medical need for more effective treatments. The company's investigational drug RMC-035 is being developed as a kidney protective treatment in connection with open heart surgery and kidney transplantation. Guard Therapeutics is listed on Nasdaq First North Growth Market Stockholm.

Certified Adviser is Svensk Kapitalmarknadsgranskning AB, tel. +46 11 32 30 732, [email protected].

This information is information that Guard Therapeutics is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-01-09 15:05 CET.

Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Nybrogatan 34
Box 5216
102 45 Stockholm

08-692 21 90

Om beQuoted